- Home
- GOSS vs CLDT Comparison
GOSS vs CLDT Comparison
Compare GOSS & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- CLDT
- Stock Information
- Founded
- GOSS 2015
- CLDT 2009
- Country
- GOSS United States
- CLDT United States
- Employees
- GOSS N/A
- CLDT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- CLDT Real Estate Investment Trusts
- Sector
- GOSS Health Care
- CLDT Real Estate
- Exchange
- GOSS Nasdaq
- CLDT Nasdaq
- Market Cap
- GOSS 347.8M
- CLDT 374.7M
- IPO Year
- GOSS 2019
- CLDT 2010
- Fundamental
- Price
- GOSS $2.47
- CLDT $7.61
- Analyst Decision
- GOSS Strong Buy
- CLDT Strong Buy
- Analyst Count
- GOSS 4
- CLDT 2
- Target Price
- GOSS $8.50
- CLDT $10.75
- AVG Volume (30 Days)
- GOSS 3.1M
- CLDT 264.3K
- Earning Date
- GOSS 08-05-2025
- CLDT 08-06-2025
- Dividend Yield
- GOSS N/A
- CLDT 4.72%
- EPS Growth
- GOSS N/A
- CLDT N/A
- EPS
- GOSS N/A
- CLDT 0.03
- Revenue
- GOSS $40,237,000.00
- CLDT $310,140,000.00
- Revenue This Year
- GOSS N/A
- CLDT N/A
- Revenue Next Year
- GOSS $30.65
- CLDT $0.45
- P/E Ratio
- GOSS N/A
- CLDT $277.86
- Revenue Growth
- GOSS N/A
- CLDT N/A
- 52 Week Low
- GOSS $0.66
- CLDT $5.83
- 52 Week High
- GOSS $2.65
- CLDT $10.00
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- CLDT 63.27
- Support Level
- GOSS $2.38
- CLDT $7.57
- Resistance Level
- GOSS $2.65
- CLDT $7.82
- Average True Range (ATR)
- GOSS 0.15
- CLDT 0.16
- MACD
- GOSS 0.03
- CLDT 0.06
- Stochastic Oscillator
- GOSS 76.67
- CLDT 76.92
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About CLDT Chatham Lodging Trust (REIT) of Beneficial Interest
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.